Spontaneously released Neisseria meningitidis outer membrane vesicles as vaccine platform: production and purification.


Journal

Vaccine
ISSN: 1873-2518
Titre abrégé: Vaccine
Pays: Netherlands
ID NLM: 8406899

Informations de publication

Date de publication:
08 11 2019
Historique:
received: 09 10 2018
revised: 14 12 2018
accepted: 31 01 2019
pubmed: 7 8 2019
medline: 30 9 2020
entrez: 7 8 2019
Statut: ppublish

Résumé

Outer membrane vesicles (OMVs) are nanoparticles produced by Gram-negative bacteria that can be used as vaccines. The application of OMVs as vaccine component can be expanded by expressing heterologous antigens on OMVs, creating an OMV-based antigen presenting platform. This study aims to develop a production process for such OMV-based vaccines and studies a production method based on meningococcal OMVs that express heterologous antigens on their surface. As a proof of concept, the Borrelia burgdorferi antigens OspA and OspC were expressed on Neisseria meningitidis OMVs to create a concept anti-Lyme disease vaccine. Production of OMVs released in the culture supernatant was induced by high dissolved oxygen concentrations and purification was based on scalable unit operations. A crude recovery of 90 mg OMV protein could be obtained per liter culture. Expressing heterologous antigens on the OMVs did result in minor reduction of bacterial growth, while OMV production remained constant. The antigen expression did not alter the OMV characteristics. This study shows that production of well characterized OMVs containing heterologous antigens is possible with high yields by combining high oxygen concentrations with an optimized purification process. It is concluded that heterologous OMVs show potential as a vaccine platform.

Identifiants

pubmed: 31383485
pii: S0264-410X(19)30161-6
doi: 10.1016/j.vaccine.2019.01.076
pii:
doi:

Substances chimiques

Antigens, Bacterial 0
Bacterial Outer Membrane Proteins 0
Bacterial Vaccines 0
Meningococcal Vaccines 0
Oxygen S88TT14065

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

6978-6986

Informations de copyright

Copyright © 2019 The Authors. Published by Elsevier Ltd.. All rights reserved.

Auteurs

Matthias J H Gerritzen (MJH)

Institute for Translational Vaccinology (Intravacc), Process Development Bacterial Vaccines, P.O. Box 450, 3720 AL Bilthoven, the Netherlands; Wageningen University, Bioprocess Engineering, P.O. Box 16, 6700 AA Wageningen, the Netherlands.

Merijn L M Salverda (MLM)

Institute for Translational Vaccinology (Intravacc), Exploratory & Clinical Research, P.O. Box 450, 3720 AL Bilthoven, the Netherlands.

Dirk E Martens (DE)

Wageningen University, Bioprocess Engineering, P.O. Box 16, 6700 AA Wageningen, the Netherlands.

René H Wijffels (RH)

Wageningen University, Bioprocess Engineering, P.O. Box 16, 6700 AA Wageningen, the Netherlands; Nord University, Faculty of Biosciences and Aquaculture, P.O. Box 1409, 8049 Bodø, Norway.

Michiel Stork (M)

Institute for Translational Vaccinology (Intravacc), Process Development Bacterial Vaccines, P.O. Box 450, 3720 AL Bilthoven, the Netherlands. Electronic address: michiel.stork@intravacc.nl.

Articles similaires

Humans Pulmonary Disease, Chronic Obstructive Exercise Tolerance Male Aged
Phonons Titanium Oxides Zirconium Calcium Compounds
Animals Aquatic Organisms Ecosystem Oxygen Thermotolerance

Human prolyl hydroxylase domain 2 reacts with O

Giorgia Fiorini, Stephen A Marshall, William D Figg et al.
1.00
Humans Ketoglutaric Acids Hypoxia-Inducible Factor-Proline Dioxygenases Oxygen Hypoxia-Inducible Factor 1, alpha Subunit

Classifications MeSH